Table 1. Characteristics of patients diagnosed with acute myeloid leukaemia and treated intensively.
ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase; N/A, not available.
| Variable | Number of patients | Percentage (%) | |
| Gender | Male | 79 | 59.40 |
| Female | 54 | 40.60 | |
| Age (years) | 18-29 | 9 | 6.77 |
| 30-39 | 11 | 8.27 | |
| 40-49 | 32 | 24.06 | |
| 50-59 | 41 | 30.83 | |
| 60-69 | 39 | 29.32 | |
| 70-79 | 1 | 0.75 | |
| Median | 53 | ||
| Year of diagnosis | 2015 | 18 | 13.53 |
| 2016 | 20 | 15.04 | |
| 2017 | 16 | 12.03 | |
| 2018 | 24 | 18.05 | |
| 2019 | 20 | 15.04 | |
| 2020 | 14 | 10.53 | |
| 2021 | 21 | 15.79 | |
| Molecular biology | Yes | 110 | 82.71 |
| N/A | 23 | 17.29 | |
| NPM1 | Mutated | 35 | 26.32 |
| Wild-type | 71 | 53.38 | |
| N/A | 27 | 20.30 | |
| FLT3 ITD | Mutated | 20 | 15.04 |
| Wild-type | 82 | 61.65 | |
| N/A | 31 | 23.31 | |
| FLT3 TKD | Mutated | 10 | 7.52 |
| Wild-type | 91 | 68.42 | |
| N/A | 32 | 24.06 | |
| Others | BCR-ABL | 1 | 0.75 |
| CBFB-MYH11 | 1 | 0.75 | |
| AML-ETO | 6 | 4.50 | |
| DEK-CAN | 1 | 0.75 | |
| NUP98-NSD1 | 1 | 0.75 | |
| Karyotype | Normal | 24 | 18.04 |
| Abnormal | 20 | 15.04 | |
| N/A | 89 | 66.92 | |
| Risk stratification | Favourable | 21 | 15.8 |
| Intermediate | 68 | 51.1 | |
| Adverse | 15 | 11.3 | |
| N/A | 29 | 21.8 | |
| Haemoglobin (g/l) | Min | 38 | |
| Max | 132 | ||
| Median | 88 | ||
| Platelets (109/l) | Min | 2 | |
| Max | 286 | ||
| Median | 41 | ||
| Leukocytes (109/l) | Min | 0.19 | |
| Max | 347 | ||
| Median | 24.3 | ||
| <40 | 77 | ||
| ≥40 to <100 | 28 | ||
| ≥100 | 28 | ||
| Peripheral blasts (%) | Min | 0 | |
| Max | 99 | ||
| Median | 35 | ||
| Bone marrow blasts (%) | Min | 20 | |
| Max | 100 | ||
| Median | 50 | ||
| Ferritin (ng/ml) | Min | 79 | |
| Max | 5364 | ||
| Median | 770 | ||
| LDH (U/L) | Min | 197 | |
| Max | 10677 | ||
| Median | 1174 | ||
| ESR (mm/h) | Min | 2 | |
| Max | 170 | ||
| Median | 88 | ||
| Fibrinogen (mg/dl) | Min | 120 | |
| Max | 1215 | ||
| Median | 435 |